Study Findings from Uniwersytet Warminsko-Mazurski w Olsztynie Broaden Understanding of Multiple Sclerosis (The mechanism of action of anti-CD20 monoclonal antibodies used in the treatment of multiple sclerosis).

A recent study conducted by researchers at Uniwersytet Warminsko-Mazurski w Olsztynie has provided new insights into the mechanism of action of anti-CD20 monoclonal antibodies used in the treatment of multiple sclerosis (MS). CD20 is a protein found on the surface of B lymphocytes, and monoclonal antibodies against CD20 can effectively eliminate these cells. Four different anti-CD20 antibodies have been studied for the treatment of MS, and while they all target the same protein, they have different molecular and pharmacological characteristics. Clinical trials have consistently shown that the elimination of B cells is an effective method for slowing down the progression of MS. However, future therapies should focus on targeting specific pathogenic groups of B lymphocytes rather than eliminating the entire population of these cells. [Extracted from the article]